Drug Trial Radar · NCT06809803
Extended-release Sodium Oxybate in Children
Last checked: Nov 20, 2026Latest source record: Nov 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Oct 27, 2025
Primary completion
Jun 2027
Study completion Jul 2027
Sponsor
- Lead sponsor
- Stanford UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Avadel
- First posted
- Feb 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 7 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objectives of this study are to determine the treatment preferences of children with narcolepsy type 1 between Extended-release sodium oxybate and Non-extended-release oxybates (Sodium oxybate or a medication with the combination of Calcium, magnesium, potassium, and sodium oxybates). The study will also assess the safety, convenience, and tolerability of Extended-release sodium oxybate. Additionally, the researchers aim to assess how well Extended-release sodium oxybate works in treating narcolepsy type 1.
Conditions
- Narcolepsy Type 1 (NT 1)
Interventions
Extended-release sodium oxybateDrug
Participants will take Extended-release sodium Oxybate (Lumryz) 4.5-9 g oral suspension in approximately ⅓ cup of water orally once a day before bedtime. Dosage of Lumryz will be the same as the equivalent total dose of the Non-Extended-release Oxybate (Xywav or Xyrem) that participants use before starting the study
Non-extended-release oxybatesDrug
Participants will take Non-Extended-release Oxybates (Xyrem oral solution or Xywav oral solution) 4.5-9 g orally per night (divided into two doses, once before bedtime and another dose 2-4 hours later) at the same dose of Xyrem or Xywav that participants use before starting the study will be continued to compare with Extended-release sodium Oxybate (Lumryz)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Participant preference for selecting the extended vs non-extended release oxybatesTime frame: Baseline, up to 8-12 weeks through study completion
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Stanford University
Redwood City, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.